Trial · NCT03256045
Results by group51
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 51
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Best Overall Response, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-82 | 4 | IMWG Uniform Response Grade | |
| Best Overall Response, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-91 | 2 | IMWG Uniform Response Grade | |
| Best Overall Response, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-92 | 2 | IMWG Uniform Response Grade | |
| Best Overall Response, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-95 | 1 | IMWG Uniform Response Grade | |
| Best Overall Response, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-96 | 1 | IMWG Uniform Response Grade | |
| Best Overall Response, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-98 | 1 | IMWG Uniform Response Grade | |
| Best Overall Response, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-99 | 3 | IMWG Uniform Response Grade | |
| Best Overall Response, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-109 | 4 | IMWG Uniform Response Grade | |
| Best Overall Response, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject M-111 | 1 | IMWG Uniform Response Grade | |
| Multiple Myeloma Cells In-vitro Drug Sensitivity to Panobinostat, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-82 | 3.8 | nM | |
| Multiple Myeloma Cells In-vitro Drug Sensitivity to Panobinostat, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-91 | 5.9 | nM | |
| Multiple Myeloma Cells In-vitro Drug Sensitivity to Panobinostat, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-92 | 2.6 | nM | |
| Multiple Myeloma Cells In-vitro Drug Sensitivity to Panobinostat, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-95 | 19.8 | nM | |
| Multiple Myeloma Cells In-vitro Drug Sensitivity to Panobinostat, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-96 | 1.3 | nM | |
| Multiple Myeloma Cells In-vitro Drug Sensitivity to Panobinostat, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-98 | 4.4 | nM | |
| Multiple Myeloma Cells In-vitro Drug Sensitivity to Panobinostat, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-99 | 8.5 | nM | |
| Multiple Myeloma Cells In-vitro Drug Sensitivity to Panobinostat, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-109 | 13.6 | nM | |
| Multiple Myeloma Cells In-vitro Drug Sensitivity to Panobinostat, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-111 | 2.0 | nM | |
| Multiple Myeloma Cells In-vitro Drug Sensitivity to Carfilzomib, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-82 | 17.5 | nM | |
| Multiple Myeloma Cells In-vitro Drug Sensitivity to Carfilzomib, by Subject | Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone | Subject MM-91 | 0.479 | nM |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03256045/results